Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Microencapsulación de islotes pancreáticos para trasplante en pacientes con diabetes tipo 1

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOGR20151123003
Publicado:
27/11/2015
Caducidad:
27/11/2016
Resumen:
Una pyme griega ha desarrollado un dispositivo muy eficiente para encapsular islotes individuales con una membrana de alta calidad de un hidrogel biocompatible que evita la necesidad de utilizar medicación inmunosupresora en trasplantes. La tecnología tiene el objetivo de hacer del trasplante de islotes una modalidad terapéutica principal para la diabetes tipo 1. Se buscan pymes e industrias en los sectores de dispositivos médicos y farmacéutico con el fin de establecer acuerdos de licencia de esta tecnología patentada.

Details

Tittle:
Microencapsulation of pancreatic cell islets for transplantation into patients with diabetes type 1
Summary:
A Greek SME has developed a high-rate, high efficiency device to encapsulate individual islets with a high-quality membrane of a biocompatible hydrogel that eliminates the need for immunosuppressive medication in transplantation. The technology aims at making transplantation of islets a mainstream therapeutic modality for diabetes type 1. The Greek SME is looking for licensing agreement of the patent-protected technology with SMEs and industry in the pharma -Y- medical device sectors.
Description:
A Greek SME has developed a high-rate, high efficiency technology to encapsulate individual islets with a high-quality membrane of a biocompatible hydrogel. The membrane allows oxygen, nutrients and insulin but not antibodies and moieties generated by the patient´s immune system reactions to transfer through it and provides for the viability of the islets during the hypoxic stage from transplantation to angiogenesis by the implant. The technology aims at making transplantation of islets a mainstream therapeutic modality for diabetes type 1.

An apparatus for microencapsulation of individual pancreatic cell islets to be transplanted into patients with diabetes type 1 has been developed and the associated technology has been patented. This apparatus can be also for encapsulation of medicinal drugs but it is mainly intended for encapsulation of viable cellular moieties.

The apparatus consists of three parts:
1. A system that feeds the islets in a single file by hydrodynamic-focusing, thus ensuring, separate encapsulation of individual islets,
2. An encapsulation chamber containing a two-layer water-oil system from which pancreatic islets are enclosed into microcapsules by selective withdrawal, and
3. A micropump to remove the islets from the encapsulation chamber for recovery by filtration.
The membrane enclosing an islet is formed by crosslinking of a biocompatible polymer. Membrane has been design with a cut-off molecular weight higher than insulin but less than the smallest antibodies. Scavenger compounds for small molecular weight toxic moieties generated by the recipient´s immune system , e.g., cytokines, chemokines, free radicals, etc., together with vascular epithelial growth factor (to induce angiogenesis) and hemoglobin with antioxidant enzymes (to protect the islet from hypoxic stress) can be incorporated in the hydrogel forming the microcapsule membrane.
The Greek SME is seeking to establish licensing agreement with the pharma and/or medical devices companies for the commercialization of the patented microencapsulation technology.

Advantages and Innovations:
1. Eliminates the need for immunosuppressive medication in transplantation as in Edmonton protocol
2. Can produce islets encapsulated by a high-quality membrane at a high rate -Y- efficiency and in numbers adequate for clinical trials (15,000 islets required per kg of patient weight)
3. Can maintain viability of transplanted islets during the hypoxic stage from transplantation to angiogenesis by the implant
4. Can maintain long-term independence from insulin and maintain a normal glycaemic level.
Stage of Development:
Available for demonstration
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Patent granted in the US

Partner sought

Type and Role of Partner Sought:
Type -Y- specific area of activity of partner sought:
SMEs -Y- industry in the pharma sector and/or developers, manufactures of medical devices

Task to be performed:
Take the product to the market under license of the patent

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Greek

Keywords

Technology Keywords:
06004 Micro y nanotecnología relacionada con las ciencias biológicas
06001013 Tecnología médica / ingeniería biomédica